Immune-mediated central nervous system (CNS) disorders, including neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG-IgG) associated disease (MOGAD), present with similar clinical and radiologic features as multiple sclerosis, which is the most common CNS demyelinating disease. Because multiple sclerosis treatment may worsen NMOSD and MOGAD, accurate diagnosis is critical.
90% of patients with NMOSD are initially misdiagnosed with multiple sclerosis1
1/3 of AQP4-IgG-negative patients are positive for MOG-IgG2
50% probability of second optic neuritis episode within one year of initial attack in AQP4-positive patients3
CNS demyelinating disease Test menu
Our unique evaluation to diagnose immune-mediated CNS demyelinating disease uses a fluorescence activated cell sorting (FACS) live cell-binding assay to detect the two most common antibodies linked to the harmful autoimmune response. Identification of aquaporin-4 (AQP4-IgG) and MOG-IgG allows for diagnostic certainty and implementation of an appropriate treatment regimen, which minimizes the risk of relapse and patient disability.
Fill out the form below and one of our specialists will be in touch.